Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
E1A binding protein p400 (EP400) is a large, multi-domain ATP-dependent chromatin remodeling factor and a core component of the human TIP60–EP400 complex, which regulates chromatin structure through both histone exchange and histone acetylation[1][2][3]. It acts as a scaffold essential for assembling this multi-protein complex and is directly involved in DNA repair via homologous recombination, transcriptional activation of genes (notably by acetylating histones H2A/H4), and cell cycle regulation[1][2][3]. EP400 binds and modulates chromatin at sites of DNA double-strand breaks, facilitates the recruitment of DNA repair machinery, and is implicated in regulating key pathways governing apoptosis and cell fate decisions—particularly via interactions with oncogenic and tumor suppressor factors such as p53 and Myc[1][3]. Dysregulation or altered expression of EP400 has been associated with several cancers. While under investigation for its role in tumorigenesis and as a potential biomarker, there are currently no approved drugs directly targeting EP400 or confirmed disease biomarkers based on EP400 modulation[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on E1A binding protein p400 (EP400).